Press Releases

Kindeva Appoints Daniel J. Speciale as the New Chief Financial Officer (CFO)

CluePoints Appoints Usama Dar as Chief Product and Technology Officer

CluePoints, provider of leading statistical and AI-driven software solutions, has today announced Usama Dar as its new Chief Product and Technology Officer.

Genomize and Genomenon Partner to Empower Researchers and Clinicians with Comprehensive Genomic Insights

Genomenon and Genomize today announced a new partnership that brings together the best of genomic intelligence and next-generation sequencing technology to transform how genomic data is interpreted. Through this integration, Genomenon’s Mastermind® Genomic Intelligence Platform and Cancer Knowledgebase (CKB) are now seamlessly embedded within Genomize’s SEQ Platform, enabling a unified and deeply enriched analysis environment. This partnership marks a major step forward in streamlining genomic analysis and advancing precision medicine—especially across Europe, the Middle East, and Asia, where Genomize is actively leading innovation.

WCG ClinSphere™ Total Feasibility Releases Self-Serve Capabilities that Optimize Clinical Trial Site Selection

WCG announced today the launch of WCG ClinSphere™ Total Feasibility’s Software-as-a-Service (SaaS) technology solution, designed to address the most important clinical trial study start-up decisions for sponsors and contract research organizations (CROs).

Inizio Medical Launches iON.AI to Transform Medical Affairs Capabilities

Andaman7 Seeks $5m to Continue Investment in Pioneering Technology

Andaman7, the platform transforming healthcare communications and bridging the gap between patients and researchers, is seeking investment to reach the next milestones in its ground-breaking journey.

PwC certifies KELES as first VC-firm to achieve SFDR Article 9 for digital health investment

Novartis Strengthens Cardiovascular Portfolio with $3.08 Billion Anthos Therapeutics Acquisition

Anthos Therapeutics, Inc., a business that produces abelacimab (full human monoclonal antibody), a late-stage medication being developed to prevent stroke and systemic embolism in patients with atrial fibrillation, has agreed to be acquired by Novartis. Upon concluding the deal, Novartis will pay $925 million upfront, subject to certain usual adjustments. If certain sales and regulatory milestones are met, Novartis may also pay an additional $2.15 billion.

Upperton Pharma Solutions Wins Champion Award at 2025 CDMO Leadership Awards in Small Molecule Dosage Form category.

Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), is proud to announce its selection as Champion Winner in the Small Molecule Dosage Form – International category at the 2025 CDMO Leadership Awards.

Femasys Gains European Approval for FemBloc Delivery System, Advancing the First Non-Surgical Option for Permanent Birth Control

European women will soon be able to receive permanent birth control through a non-surgical approach. FemBloc, developed by Femasys, a leading biomedical innovator addressing significant unmet needs in women's health worldwide, announces Conformité Européene (CE) mark certification under the European Union Medical Device Regulation (EU MDR) as the first regulatory approval in the world for the FemBloc® delivery system for non-surgical female permanent birth control.

Coronado Research Announce the Appointment of Gary Lyons as EVP Medical Affairs

Coronado Research has appointed Gary Lyons as EVP Medical Affairs. Gary is a seasoned senior Medical Affairs leader with extensive strategic and operational implementation experience across the industry and product lifecycle.

CariGenetics launches Caribbean Genome Programme with Oxford Nanopore to drive regional genomic research

CariGenetics and Oxford Nanopore Technologies have launched the Caribbean Genome Programme, the first large-scale genomic sequencing initiative in the region. This pioneering effort is set to address unmet need in advancing regional genetic research in the Caribbean, providing real-time, high throughput sequencing to address critical health disparities, starting with men’s health.

START Further Expands Its Global Oncology Site Network with the Addition of Carolina Urologic Research Center

START's site network solidifies its global leadership in urological cancer trials.

Coronado Research Announce the Appointment of Nick Littlebury as EVP, Regulatory Affairs

Coronado Research has appointed Nick Littlebury as EVP, Regulatory Affairs. Nick is a senior regulatory leader with extensive strategic and operational experience across the pharmaceutical industry's product lifecycle.

The Biotech Roadshow: Shaping the Future of Clinical Trials

The Biotech Roadshow: Shaping the Future of Clinical Trials with Expert Insights will take place in person on Tuesday, 25th March at Alderley Park, Macclesfield, UK from 10 am to 2 pm

Qureight and Remedy Cell partner to integrate deep learning platform into Phase 1b study of RC-0315 in IPF

Qureight Ltd. and Remedy Cell are integrating the latest AI deep learning technology into a Phase 1b study of RC-0315, to develop a novel therapy for the fatal lung condition Idiopathic Pulmonary Fibrosis (IPF).

Lindus Health and Sooma Medical announce pivotal device clinical trial for treatment of MDD

Lindus Health and Sooma Medical announce pivotal device clinical trial for treatment of MDD

Mural Health and ICON Announce Partnership to Enhance Participant and Site Experience in Clinical Trials

Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc (NASDAQ: ICLR), a global healthcare intelligence and clinical research organization, today announce a partnership to utilize the participant management and payments platform, Mural Link.

Owkin Launches ATLANTIS: An Extensive Multimodal Patient Data Discovery Program Across 7 Countries in 11 Therapeutic Areas

Owkin, a pioneer in Agentic AI for decoding the complexities of biology, has launched a comprehensive multimodal patient data discovery program to accelerate multimodal data access and advance medical research.

TrialValue Unveils Groundbreaking Human-Augmented Analytics Intelligence Budget Prediction Engine for Clinical Trials

TrialValue, a platform by RHIEOS Ventures Ltd (UK), has launched a groundbreaking human-augmented analytics intelligence budget prediction engine for clinical trials. Originally developed in 2018 using machine learning, curated datasets, and real-world data, this innovation generates full trial budgets with minimal assumptions, offering speed, confidence, and accuracy. The tool provides financial optimization recommendations and empowers stakeholders to make informed decisions. Larry Ajuwon, Director of RHIEOS Ventures, calls it “TrialValue Clinical R&D Financial Benchmarking’s new deal.” TrialValue aims to enhance financial efficiency in clinical development, reducing delays and uncertainties.